Peter Boström
peter.bostrom@utu.fi |
- Detection of Prostate Cancer Using Biparametric Prostate MRI, Radiomics, and Kallikreins: A Retrospective Multicenter Study of Men With a Clinical Suspicion of Prostate Cancer (2022)
- Journal of Magnetic Resonance Imaging
- Evolving imaging methods of prostate cancer and the emergence of magnetic resonance imaging guided ablation techniques (2022)
- Frontiers in Oncology
- Incidence of and mortality from Bacille Calmette-Guerin (BCG) infections after BCG instillation therapy (2022)
- BJU International
- Increased Expression and Altered Cellular Localization of Fibroblast Growth Factor Receptor-Like 1 (FGFRL1) Are Associated with Prostate Cancer Progression (2022)
- Cancers
- Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD V.2.0) (2022)
- BMJ Open
- Integrins are enriched on aberrantly fucosylated tumour‐derived urinary extracellular vesicles (2022)
- Journal of Extracellular Biology
- Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12-month clinical outcomes of a phase I study (2022)
- BJU International
- Mortality after surgery for benign prostate hyperplasia: a nationwide cohort study (2022)
- World Journal of Urology
- Periodic trends in geographical variation of prostate cancer incidence and mortality in Finland between 1985 and 2019 (2022)
- Acta Oncologica
- Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging–detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score (2022)
- European Urology
- Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients (2022)
- Urologic Oncology: Seminars and Original Investigations
- Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol (2022)
- BMJ Open
- The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator (2022)
- European Urology Open Science
- The variant rs77559646 associated with aggressive prostate cancer disrupts ANO7 mRNA splicing and protein expression (2022)
- Human Molecular Genetics
- Uptake of 18F-rhPSMA-7.3 in Positron Emission Tomography Imaging of Prostate Cancer: A Phase 1 Proof-of-Concept Study (2022)
- Cancer Biotherapy and Radiopharmaceuticals
- Accurate Prostate Cancer Detection and Segmentation Using Non-Local Mask R-CNN With Histopathological Ground Truth (2021)
- International Journal of Radiation Oncology - Biology - Physics
- A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE) (2021)
- European Urology Oncology
- A three-feature prediction model for metastasis-free survival after surgery of localized clear cell renal cell carcinoma (2021)
- Scientific Reports
- Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD). (2021)
- European Urology Oncology
- Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study (2021)
- npj Precision Oncology